Clinical Trials Logo

Clinical Trial Summary

The goal of this Phase I Open-Label study is to demonstrate the safety and feasibility of VentriGel injection in children with Hypoplastic Left Heart Syndrome (HLHS). The main questions it aims to answer are: - Whether VentriGel is safe in treating patients with HLHS - Whether there are any preliminary improvements in measures of cardiac function following Ventrigel injection


Clinical Trial Description

HLHS, a type of congenital heart disease, presents a unique challenge where the left ventricle fails to develop, necessitating the right ventricle to manage both systemic and pulmonary blood flow. This condition, once fatal, has become manageable due to advancements in surgical techniques, with reported 5-year survival rates of 70-90%. However, these staged procedures, while lifesaving, can strain the right ventricle, leading to long-term issues such as weakened muscle and reduced cardiac function. Additionally, even with surgical intervention, patients often face a diminished quality of life. Addressing these challenges, ongoing clinical trials explore regenerative therapies, particularly stem cell injections, aiming to improve heart function. Yet, concerns persist regarding the practicality and efficacy of these treatments, including issues with cell survival and coordination of injections within narrow timeframes. Innovatively, the investigator and the team propose an alternative approach using VentriGel, an injectable hydrogel derived from decellularized porcine myocardium. Originally designed for treating heart failure post-myocardial infarction in adults, VentriGel has shown promising results in animal models, demonstrating significant improvements in cardiac function. Notably, its shelf-stable nature and flexible timing for administration offer advantages over traditional stem cell therapies. Moreover, VentriGel's effectiveness in addressing right-ventricular failure, as demonstrated in recent studies, highlights its potential as a solution for HLHS patients. Leveraging approved extracellular matrix devices, such as Alloderm and SurgiSIS, further underscores the feasibility and safety of this approach, paving the way for potentially transformative treatments in congenital heart diseases. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06461676
Study type Interventional
Source Emory University
Contact William Mahle, MD
Phone 404-256-2593
Email MahleW@kidsheart.com
Status Not yet recruiting
Phase Phase 1
Start date October 1, 2024
Completion date September 30, 2027

See also
  Status Clinical Trial Phase
Completed NCT01215240 - Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure N/A
Completed NCT00513240 - Erythropoetin Neuroprotection for Neonatal Cardiac Surgery Phase 1/Phase 2
Withdrawn NCT00156455 - Sleep Disordered Breathing in Children With Single Ventricle Physiology N/A
Terminated NCT01445041 - Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome Phase 1
Recruiting NCT04581668 - Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease N/A
Completed NCT01708863 - A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation
Completed NCT01736956 - Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome N/A
Recruiting NCT03406884 - The CHILD Trial: Hypoplastic Left Heart Syndrome Study. Phase 1
Active, not recruiting NCT03079401 - Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle Phase 1/Phase 2
Completed NCT02306057 - Fluid Balance in Children Undergoing Fontan Surgery N/A
Terminated NCT01107990 - Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques
Completed NCT01883076 - Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome Phase 1
Completed NCT04056416 - Physical Activity Promotion in Children and Adolescents With Single Ventricle Physiology (MedBike) N/A
Completed NCT01656941 - Genetic Determinants of Congenital Heart Disease Outcomes
Completed NCT00464100 - Near-infrared Spectroscopy (NIRS) Neurodevelopmental Outcomes
Active, not recruiting NCT03779711 - Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome Phase 2
Recruiting NCT04925024 - Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. Phase 2
Recruiting NCT02781922 - Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial) Phase 3
Completed NCT01582529 - SVRII Family Factors Study
Completed NCT00974025 - Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients N/A